首页> 外国专利> EBI3, DLX5, NPTX1 AND CDKN3 FOR TARGET GENES OF LUNG CANCER THERAPY AND DIAGNOSIS

EBI3, DLX5, NPTX1 AND CDKN3 FOR TARGET GENES OF LUNG CANCER THERAPY AND DIAGNOSIS

机译:EBI3,DLX5,NPTX1和CDKN3用于肺癌治疗和诊断的靶基因

摘要

The present invention relates to methods for treating or preventing lung cancer by administering a double-stranded molecule against one or more of EBI3, DLX5, NPTXl, CDKN3 or EF-I delta genes or compositions, vectors or cells containing such a double-stranded molecule. The present invention also features methods for diagnosing lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among EBI3, DLX5, NPTXl, CDKN3 and/or EF-I delta. Also disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of EBI3, DLX5, CDKN3 and/or EF-I delta in the lung cancer, the cell proliferation function of one or more of EBI3, DLX5, NPTXl, CDKN3 and/or EF-I delta or the interaction between CDKN3 and VRS, EF-I beta, EF-I gamma and/or EF-I delta.
机译:本发明涉及通过施用针对EBI3,DLX5,NPTX1,CDKN3或EF-1δ基因中的一个或多个的双链分子或包含这种双链分子的组合物,载体或细胞来治疗或预防肺癌的方法。本发明还特征在于使用选自EBI3,DLX5,NPTX1,CDKN3和/或EF-1δ的一种或多种过表达基因来诊断肺癌,尤其是NSCLC或SCLC的方法。还公开了鉴定用于治疗和预防肺癌的化合物的方法,以其对肺癌中EBI3,DLX5,CDKN3和/或EF-1δ中的一个或多个的过度表达,细胞增殖的作用为指标。 EBI3,DLX5,NPTX1,CDKN3和/或EF-1δ中的一个或多个的功能或CDKN3与VRS,EF-1 beta,EF-1γ和/或EF-1δ之间的相互作用。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号